Key takeaways
Rinvoq (upadacitinib) and Xeljanz (tofacitinib) are both JAK inhibitors used to treat inflammatory conditions like rheumatoid arthritis and ulcerative colitis. However, they have some differences. Rinvoq is available as an extended-release tablet and an oral solution, while Xeljanz comes in immediate-release and extended-release tablets, as well as a liquid form. Rinvoq is typically taken once daily, whereas Xeljanz can be taken once or twice daily, depending on the formulation. Both medications are approved to treat additional inflammatory conditions; Rinvoq is approved for eczema and Crohn's disease, but Xeljanz is not. Common side effects of Rinvoq include acne and upper respiratory infections, while Xeljanz may cause diarrhea and headaches. Both medications can increase the risk of serious infections and blood clots. Rinvoq and Xeljanz both interact with many medications, including grapefruit juice. Both medications require careful monitoring and should not be used with live vaccines.
